Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association Between Participant Satisfaction and Self-Reported Clinical Practice Behaviors in a Nationwide Guideline Education Program.

Neuropsychopharmacology reports·2026
Same author

An open-label, long-term extension, multicenter study to evaluate the safety and efficacy of venlafaxine extended release in Japanese outpatients with generalized anxiety disorder.

PCN reports : psychiatry and clinical neurosciences·2026
Same author

Baseline working memory was associated with improvement in psychological quality of life in patients with persistent depressive symptoms: a prospective observational study.

Frontiers in psychiatry·2026
Same author

A preliminary cross-sectional study of bipolarity and primary pharmacotherapy in long-term stable patients with major depressive disorder.

International journal of bipolar disorders·2026
Same author

Pharmacological treatment of schizophrenia: Japanese Expert Consensus 2025.

Schizophrenia (Heidelberg, Germany)·2026
Same author

Factors associated with social functioning by relapse frequency in Japanese outpatients with schizophrenia: the Multicenter Treatment Survey and Assessments for Schizophrenia in Psychiatric Clinics (MUSASI).

Psychological medicine·2026

Related Experiment Video

Updated: May 19, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K

Antidepressant Prescribing Patterns At Initial Visits for Patients With Mild Depression: A Retrospective Study.

Minoru Urata1, Jonathan Liao2, Takashi Tsuboi1

  • 1Department of Neuropsychiatry, Kyorin University School of Medicine, Mitaka, Japan.

Pharmacopsychiatry
|April 8, 2026
PubMed
Summary

Antidepressants were prescribed to nearly 30% of mild depression patients initially. Specific symptom profiles did not strongly predict antidepressant prescription, indicating other factors influence treatment decisions.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.9K
Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

894

Related Experiment Videos

Last Updated: May 19, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.9K
Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

894

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • The effectiveness of antidepressants for mild depression is debated.
  • Clinical guidelines suggest prioritizing psychosocial interventions for mild depression.
  • However, antidepressants are frequently prescribed in real-world settings.

Purpose of the Study:

  • To examine antidepressant prescribing patterns in initial consultations for mild depression.
  • To identify symptom-related factors influencing these prescribing decisions.

Main Methods:

  • Retrospective chart review of 1,508 outpatients diagnosed with depression.
  • Analysis of 171 patients meeting mild depression criteria (Quick Inventory of Depressive Symptomatology-Self Report score 6-10).
  • Independent t-tests and logistic regression to compare groups.

Main Results:

  • 28.1% of mild depression patients received antidepressants at the first visit.
  • No significant demographic or overall symptom severity differences between groups.
  • No specific symptom item robustly predicted antidepressant prescription.

Conclusions:

  • Antidepressants are prescribed in about 30% of initial mild depression consultations.
  • Prescribing decisions appear influenced by factors beyond specific symptom profiles.
  • Further research is needed to understand real-world treatment selection for mild depression.